v3.26.1
Schedule of Financial Information by Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Net revenues $ 26,550 $ 54,220
Cost of revenues (excluding amortization of acquired intangible assets) 20,074 14,989
Direct expenses 27,487 38,326
Segment contribution (21,011) 905
Other general and administrative expenses 38,804 37,703
Amortization 1,493  
Loss from operations (61,308) (38,358)
Other expenses (30,405) (19,534)
Loss before income taxes (91,713) (57,892)
Indirect expenses   1,560
Change in fair value of contingent consideration liability (193)
Amortization 1,493 1,753
Total indirect expenses   1,560
Cell Therapy [Member]    
Segment Reporting Information [Line Items]    
Net revenues 3,807 688
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses 13,194 15,807
Segment contribution (9,387) (15,119)
Biobanking [Member]    
Segment Reporting Information [Line Items]    
Net revenues 5,432 5,140
Cost of revenues (excluding amortization of acquired intangible assets) 859 1,172
Direct expenses 1,371 1,673
Segment contribution 3,202 2,295
Degenerative Disease [Member]    
Segment Reporting Information [Line Items]    
Net revenues 17,311 48,392
Cost of revenues (excluding amortization of acquired intangible assets) 19,215 13,817
Direct expenses 12,922 20,846
Segment contribution $ (14,826) $ 13,729